Authors:
Propper, DJ
McDonald, AC
Man, A
Thavasu, P
Balkwill, F
Braybrooke, JP
Caponigro, F
Graf, P
Dutreix, C
Blackie, R
Kaye, SB
Ganesan, TS
Talbot, DC
Harris, AL
Twelves, C
Citation: Dj. Propper et al., Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C, J CL ONCOL, 19(5), 2001, pp. 1485-1492
Authors:
Katso, RMT
Manek, S
Ganjavi, H
Biddolph, S
Charnock, MFL
Bradburn, M
Wells, M
Ganesan, TS
Citation: Rmt. Katso et al., Overexpression of H-Ryk in epithelial ovarian cancer: Prognostic significance of receptor expression, CLIN CANC R, 6(8), 2000, pp. 3271-3281
Authors:
Braybrooke, JP
O'Byrne, KJ
Propper, DJ
Blann, A
Saunders, M
Dobbs, N
Han, C
Woodhull, J
Mitchell, K
Crew, J
Smith, K
Stephens, R
Ganesan, TS
Talbot, DC
Harris, AL
Citation: Jp. Braybrooke et al., A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis, CLIN CANC R, 6(12), 2000, pp. 4697-4704
Authors:
Braybrooke, JP
Vallis, KA
Houlbrook, S
Rockett, H
Ellmen, J
Anttila, M
Ganesan, TS
Harris, AL
Talbot, DC
Citation: Jp. Braybrooke et al., Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine, CANC CHEMOT, 46(1), 2000, pp. 27-34
Authors:
Odunsi, KO
van Ee, CC
Ganesan, TS
Shelling, AN
Citation: Ko. Odunsi et al., Evaluation of the possible protective role of adeno-associated virus type 2 infection in HPV-associated premalignant disease of the cervix, GYNECOL ONC, 78(3), 2000, pp. 342-345
Authors:
Braybrooke, JP
Propper, DJ
O'Byrne, KJ
Koukourakis, MI
Patterson, AV
Houlbrook, S
Love, SD
Varcoe, S
Taylor, M
Ganesan, TS
Talbot, DC
Harris, AL
Citation: Jp. Braybrooke et al., Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid andinterferon alpha, BR J CANC, 83(2), 2000, pp. 219-224
Authors:
Propper, DJ
Braybrooke, JP
Levitt, NC
O'Byrne, KO
Christodoulos, K
Han, C
Talbot, DC
Ganesan, TS
Harris, AL
Citation: Dj. Propper et al., Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine, BR J CANC, 82(11), 2000, pp. 1759-1763
Authors:
Propper, DJ
Levitt, NC
O'Byrne, K
Braybrooke, JP
Talbot, DC
Ganesan, TS
Thompson, CH
Rajagopalan, B
Littlewood, TJ
Dixon, RM
Harris, AL
Citation: Dj. Propper et al., Phase II study of the oxygen saturation curve left shifting agent BW12C incombination with the hypoxia activated drug mitomycin C in advanced colorectal cancer, BR J CANC, 82(11), 2000, pp. 1776-1782
Authors:
Propper, DJ
Saunders, MP
Salisbury, AJ
Long, L
O'Byrne, KJ
Braybrooke, JP
Dowsett, M
Taylor, M
Talbot, DC
Ganesan, TS
Harris, AL
Citation: Dj. Propper et al., Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: Toxicity, hormonal, and immunological effects, CLIN CANC R, 5(7), 1999, pp. 1682-1689
Authors:
Propper, DJ
Braybrooke, JP
Taylor, DJ
Lodi, R
Styles, P
Cramer, JA
Collins, WCJ
Levitt, NC
Talbot, DC
Ganesan, TS
Harris, AL
Citation: Dj. Propper et al., Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours, ANN ONCOL, 10(8), 1999, pp. 923-927
Authors:
O'Byrne, KJ
Philip, PA
Propper, DJ
Braybrooke, JP
Saunders, MP
Bates, NP
Taylor, MA
Madigan, D
Ganesan, TS
Talbot, DC
Harris, AL
Citation: Kj. O'Byrne et al., A phase II study of the modulation of 5-fluorouracil and folinic acid withhigh-dose infusional hydroxyurea in metastatic colorectal carcinoma, ANN ONCOL, 10(8), 1999, pp. 981-983
Citation: Rm. Katso et al., Functional analysis of H-Ryk, an atypical member of the receptor tyrosine kinase family, MOL CELL B, 19(9), 1999, pp. 6427-6440
Authors:
Katso, RMT
Manek, S
Biddolph, S
Whittaker, R
Charnock, MFL
Wells, M
Ganesan, TS
Citation: Rmt. Katso et al., Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: Correlation with up-regulation in epithelial ovarian cancer, CANCER RES, 59(10), 1999, pp. 2265-2270
Authors:
O'Byrne, KJ
Koukourakis, MI
Saunders, MP
Salisbury, AJ
Isaacs, R
Varcoe, S
Taylor, M
Ganesan, TS
Harris, AL
Talbot, DC
Citation: Kj. O'Byrne et al., Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer, BR J CANC, 77(11), 1998, pp. 1950-1956